Can Medication Be Prescribed Online? What New York Rules Allow
Telepsychiatry is widely used, but if a specific medication can be prescribed entirely online depends on two legal layers: federal controlled‑substance law and New York State medical practice rules. For most psychiatric medications the answer is straightforward: a licensed psychiatrist can evaluate a patient by video and send an electronic prescription to a pharmacy. For a narrower set of drugs, however, different rules apply and patients should know which category their medication falls into before choosing a telehealth practice.
Two Medication Categories That Determine Access
Psychiatric medications fall into two practical groups. Non‑controlled medications include most antidepressants such as selective serotonin reuptake inhibitors and serotonin‑norepinephrine reuptake inhibitors, mood stabilizers, antipsychotics, and non‑stimulant ADHD medications such as atomoxetine and viloxazine. These drugs are not subject to the federal in‑person requirement that governs controlled substances, and New York does not impose a separate in‑person prerequisite for them. A clinician can perform a full diagnostic evaluation by video, prescribe these medications electronically, and manage follow up care remotely under the same clinical standards that apply in an office setting.
Controlled substances include stimulant medications commonly used for ADHD, many benzodiazepines prescribed for anxiety, and certain sleep medications that are scheduled. These drugs are governed by the federal Ryan Haight Act and related Drug Enforcement Administration rules, which historically required at least one in‑person medical examination before a controlled substance could be prescribed via telemedicine. During the COVID‑19 public health emergency federal agencies temporarily waived that in‑person requirement and allowed DEA‑registered prescribers to initiate controlled‑substance prescriptions by telehealth under defined conditions. The availability of controlled‑substance prescribing by telehealth therefore depends on if a federal waiver or special registration is in effect and on the precise terms of any final rule.
New York’s 2025 Regulatory Position
In 2025 New York amended its controlled‑substance telemedicine regulations to clarify the state position. The amendments reaffirm an in‑person evaluation as the baseline requirement for prescribing controlled substances by telemedicine while also specifying limited exceptions that align with federal telehealth flexibilities. In practice this means New York preserves an in‑person baseline but allows the federal exception to operate for patients in the state when federal law or a valid federal waiver permits telehealth initiation of controlled substances. While federal flexibility remains available, many DEA‑registered telemedicine providers have been able to prescribe stimulants and certain benzodiazepines to New York residents by video. If federal flexibilities are withdrawn or narrowed, New York’s baseline in‑person requirement would again control unless a new federal special registration pathway or other federal authorization applies.
What This Means for Patients Choosing Telepsychiatry in New York
If you seek treatment with an antidepressant, mood stabilizer, antipsychotic, or a non‑stimulant ADHD medication, a telehealth‑only practice can generally manage your care from intake through ongoing medication management without an in‑person visit. If you take or expect to take a stimulant or a benzodiazepine, the situation is more conditional. Confirm if the provider is DEA‑registered, if they currently prescribe controlled substances to New York residents by telehealth, and how they will handle continuity of care if federal telehealth flexibilities change. A telehealth practice that cannot or will not provide an in‑person visit in New York may be unable to continue prescribing controlled substances if federal exceptions expire, so being in the know of a practice’s contingency plan is essential.
Practical Considerations Beyond Statutes
Pharmacies and insurers sometimes impose verification steps, prior authorization requirements, or dispensing limits that affect access to controlled medications even when a prescription is legally valid. Enforcement priorities and interpretations by regulators can shift, and real‑world practice varies among providers and pharmacies. For that reason, ask any telepsychiatry provider how often they successfully prescribe controlled substances to New York patients, if local pharmacies routinely fill those prescriptions, and if the provider will coordinate an in‑person visit in New York if required. If you travel or move between states, notify your provider because prescribing rules vary by state and a prescription valid in New York may not be lawful elsewhere.
Questions to Ask & Steps to Protect Continuity of Care
Before committing to a telehealth practice, request clear, written answers about controlled‑substance prescribing, DEA registration, and contingency plans for refills and continuity. Ask if the practice relies on federal waivers or a special registration pathway, if they will arrange or refer you for an in‑person evaluation in New York if necessary, and how they handle pharmacy or insurer hurdles. Keep copies of your medication history and recent clinical notes, maintain communication with your local pharmacy, and request a written plan that specifies how refills will be handled if regulatory changes occur. If you have complicated medical or substance use history, seek a provider who documents thorough risk assessment and monitoring practices, including periodic in‑person visits when clinically indicated, to ensure safe, effective, and legally compliant care continuity.
Bottom Line
Most psychiatric medications can be prescribed by telehealth in New York without an in‑person visit. Controlled substances are subject to a different legal regime: New York’s 2025 regulations preserve an in‑person baseline while recognizing federal exceptions that have, at times, allowed teleprescribing of stimulants and benzodiazepines. Because federal rulemaking and temporary waivers have changed over recent years and may change again, patients who rely on controlled substances should confirm a telehealth provider’s legal basis for prescribing, their DEA registration status, and their plan for continuity if federal flexibilities end. Clear, written answers from a prospective practice will protect continuity of care and avoid surprises.